Cholesterol metabolism and resistance to tamoxifen.

Marc Poirot 1, * Sandrine Silvente-Poirot 2, 3 Ralph Weichselbaum 4, *
* Auteur correspondant
1 Métabolisme du cholestérol et innovations thérapeutiques en oncologie
Institut Claudius Regaud, CRCT - Centre de Recherche en Cancérologie de Toulouse
4 Department of Radiation and Cellular Oncology
Department of Radiation and Cellular Oncology
Abstract : The oncoprotein MUC-1 was shown to upregulate the transcription of genes encoding cholesterol and lipid metabolic enzymes and correlated with a resistance to Tamoxifen (Tam) despite the presence of estrogen receptor α in breast cancer tumors. The importance of this observation is supported by molecular studies on Tam suggesting two additional pharmacological targets involved in cholesterol metabolism. These observations demonstrate the potential importance of cholesterol and lipid metabolism in the pharmacology/therapeutic effects of Tam.
Type de document :
Article dans une revue
Current Opinion in Pharmacology, Elsevier, 2012, 12 (6), pp.683-9. 〈10.1016/j.coph.2012.09.007〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00743466
Contributeur : Marc Poirot <>
Soumis le : vendredi 19 octobre 2012 - 09:43:10
Dernière modification le : jeudi 9 novembre 2017 - 09:38:02

Identifiants

Collections

Citation

Marc Poirot, Sandrine Silvente-Poirot, Ralph Weichselbaum. Cholesterol metabolism and resistance to tamoxifen.. Current Opinion in Pharmacology, Elsevier, 2012, 12 (6), pp.683-9. 〈10.1016/j.coph.2012.09.007〉. 〈inserm-00743466〉

Partager

Métriques

Consultations de la notice

168